摘要：

A nicotine receptor agonist, for example nicotine, may be used in the treatment of dyskinesias associated with dopaminergic agent therapy. This is especially useful in the treatment of Parkinson's disease with L-DOPA where the side-effect of dyskinesias brought about by administration of L-DOPA are reduced. The nicotine receptor agonist and dopaminergic agent may be used in conjunction with a third agent to achieve a therapeutic effect with the said dopaminergic agent or for treatment of a side-effect of the said dopaminergic agent. The third agent may be amantadine, carbidopa or entacapone.

展开